Catherine Berry
Biographic Data
| ID | 9073141 |
|---|---|
| NAME | Catherine Berry |
| GIVEN NAMES | Catherine |
| FAMILY NAME | Berry |
| SIGNATURE | BERRY C |
| AFFILIATIONS | Médecins Sans Frontières |
| ORCID | 0000-0001-6363-9387 |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2022 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
Prevalence, treatment, and outcomes of hepatitis C in an MDR/RR-TB trial cohort
Tuberculosis (TB) and chronic hepatitis C virus infection (HCV) remain significant global health challenges, especially in low- and middle-income countries. In Eastern Europe, a considerable percentage of multi-drug resistant (MDR) and rifampicin resistant (RR) TB populations show high HCV prevalence. Current WHO guidelines do not routinely advise HCV testing during MDR-TB treatment, despite HCV being a risk factor for drug-induced liver complica…
Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis
Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent evidence from the TB-PRACTECAL trial countries are considering programmatic uptake of 6-month, all-oral treatment regimens. We used a Markov model to estimate the incremental cost-effectiveness of three regimens containing bedaquiline, pretomanid and linezolid (BPaL) with and without mo…
No prominent works on this page.
Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis
Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent evidence from the TB-PRACTECAL trial countries are considering programmatic uptake of 6-month, all-oral treatment regimens. We used a Markov model to estimate the incremental cost-effectiveness of three regimens containing bedaquiline, pretomanid and linezolid (BPaL) with and without mo…
Prevalence, treatment, and outcomes of hepatitis C in an MDR/RR-TB trial cohort
Tuberculosis (TB) and chronic hepatitis C virus infection (HCV) remain significant global health challenges, especially in low- and middle-income countries. In Eastern Europe, a considerable percentage of multi-drug resistant (MDR) and rifampicin resistant (RR) TB populations show high HCV prevalence. Current WHO guidelines do not routinely advise HCV testing during MDR-TB treatment, despite HCV being a risk factor for drug-induced liver complica…
Internal Medicine (2 works) · Medicine (2 works) · Tuberculosis (2 works) · Tuberculosis Research and Epidemiology (2 works) · Adverse effect (1 work) · Antibiotics (1 work) · Bedaquiline (1 work) · Cohort (1 work) · Cohort study (1 work) · Cost effectiveness (1 work)